Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products. The company’s products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Future Prospects | Delve into ZBH's Long Range Plan targeting mid-single-digit revenue growth and EPS growth at 1.5x revenue rate, amid market challenges and opportunities |
Strategic Expansion | Explore Zimmer Biomet's $1.1B acquisition of Paragon 28, positioning the company in the $5B Foot & Ankle Orthopedics market for diversified growth |
Financial Resilience | Despite ERP implementation hurdles, ZBH reports $1.82B Q3 sales. Analysts set price targets ranging from $101 to $140, with an average around $125 |
Orthopedic Innovato | Zimmer Biomet navigates challenges while maintaining mid-single-digit growth, leveraging a robust product pipeline including ROSA Shoulder and new knee implants |
Metrics to compare | ZBH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZBHPeersSector | |
---|---|---|---|---|
P/E Ratio | 19.5x | −12.4x | −0.4x | |
PEG Ratio | −8.47 | 0.00 | 0.00 | |
Price / Book | 1.4x | 3.2x | 2.6x | |
Price / LTM Sales | 2.3x | 2.4x | 3.0x | |
Upside (Analyst Target) | 14.0% | 73.5% | 52.3% | |
Fair Value Upside | Unlock | 3.7% | 9.4% | Unlock |